CN201012188Y - Infection-resisted bone grafting carrier - Google Patents
Infection-resisted bone grafting carrier Download PDFInfo
- Publication number
- CN201012188Y CN201012188Y CNU2006200784096U CN200620078409U CN201012188Y CN 201012188 Y CN201012188 Y CN 201012188Y CN U2006200784096 U CNU2006200784096 U CN U2006200784096U CN 200620078409 U CN200620078409 U CN 200620078409U CN 201012188 Y CN201012188 Y CN 201012188Y
- Authority
- CN
- China
- Prior art keywords
- carrier
- bone
- slow
- infective
- morphogenetic protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The utility model relates to a bone-replant carrier, in particular to an anti-infective bone replant carrier, which can realize the stage one bone replant under the condition of the polluted or infected bone lack. The device is characterized in that a diluting-dulling carrier is arranged in the loose bone carrier of the albumen in the bone state; bone state generating albumen is arranged in the loose bone carrier of the albumen in the bone state. The carrier is cubic. An obligated hole for the diluting-dulling carrier is arranged on one plane along the long axis. The obligated hole for the diluting-dulling carrier is provided with a diluting-dulling carrier. The anti-infective bone replant carrier is simple and convenient in the manufacture, which can be finished in the normal temperature and the normal pressure without any additional chemical reagent. The device will enhance the safety of the preparation, is adaptable to be produced in large scale; the time for diluting-dulling inside of the body will be prolonged as well as enhancing the cure effect.
Description
Technical field
This utility model relates to a kind of bone and transplants carrier, the particularly a kind of Anti-infective bone transplantation carrier that can realize the first phase bone grafting under the damaged environment of bone that pollutes or infect.
Background technology
Advocate the method for drug application local sustained release and cooperate bone grafting material when treatment at present exists the bone that pollutes or infect damaged, first phase debridement than before, systemic administration, treat after the infection control method of the second stage of bone grafting again, have easy, the whole body toxic and side effects is little, the more effective characteristics of treatment.The polymethyl methacrylate of often using in the past (PMMA) is as the bone grafting material carrier of drug sustained release system, because of its unfavorable reason of biophysics performance such as do not degrade progressively is eliminated.Recently Yan Zhi infection reconstituted bone xenograft (ARBX) is with the medicine local sustained release with the bone that strengthens bone grafting material is induced and the theory of bone conductibility combines, in clinical treatment, played comparatively ideal effect, but the preparation process of the gelatin polycaprolactone drug sustained release system of wherein using is comparatively complicated, ambient parameters such as temperature are had relatively high expectations, and relate to number of chemical reagent, particularly oxolane wherein not only has severe toxicity but also volatile, has brought a lot of inconvenience and danger to operation.The mode of this medicament slow release is the surface that the gelatin polycaprolactone is wrapped in the spongy bone carrier in addition, so have only after the degraded that slow-released carrier acquires a certain degree after being implanted in the body, tissue on every side and body fluid can be opened and be penetrated in the middle of the spongy bone carrier, this could begin the process of bone defect repair, and this can be understood as the reparation that has delayed fracture in order to realize the anti-infective effect to a certain extent.
Summary of the invention
The purpose of this utility model provides a kind of Anti-infective bone transplantation carrier, it rational in infrastructure, preparation process is easy, can finish under the normal temperature and pressure, do not need other chemical reagent, improved the safety of preparation, be fit to large-scale production, the sustained release profile in vivo test time also obtains prolonging, and has improved the effect of treatment.
The technical scheme that its technical problem that solves this utility model adopts is that a kind of Anti-infective bone transplantation carrier is characterized in that: being compounded with in the spongy bone carrier of bone morphogenetic protein has slow-released carrier.
The spongy bone carrier of described bone morphogenetic protein has bone morphogenetic protein.
The spongy bone carrier of described bone morphogenetic protein is a cube, and the reserving hole of slow-released carrier is arranged at one upper edge, a plane major axis.
Be embedded with slow-released carrier in the middle of the reserving hole of the spongy bone carrier of described bone morphogenetic protein.
Quantity, the shape of the reserving hole on the spongy bone carrier of the quantity of described slow-released carrier, shape and bone morphogenetic protein are identical, and size matches.
Described slow-released carrier is the slow-released carrier of calcium phosphate bone cement or gelatin or collagen and fibrin glue material.
The spongy bone carrier of described bone morphogenetic protein is 1 * 1 * 1.5cm
3Cube, at its 1 * 1cm
2Upper edge, plane major axis the reserving hole of 2-9 equally distributed diameter 1mm is arranged.
The spongy bone carrier of described bone morphogenetic protein has the bone morphogenetic protein of 8mg.
Described slow-released carrier is diameter 1mm, and length is 15mm, cylinder or the corner angle cylinder of centre-to-centre spacing border for being symmetrically distributed, and adjacent column body or corner angle cylinder centre-to-centre spacing are the equally spaced antibiotic calcium phosphate bone cement that contains.
Characteristics of the present utility model are: slow-released carrier is replaced by is compounded with the antibiotic calcium phosphate bone cement of appropriate amount, and the calcium phosphate bone cement post is nested in the spongy bone carrier that is compounded with bone morphogenetic protein (BMP), according to the Hichugi equation, it increases the contact area of calcium phosphate bone cement and body fluid on the one hand, the degraded of accelerated material, not only bone cement itself has slow releasing function to medicine on the other hand, and the spongy bone carrier has delayed the release of medicine equally after tissue is opened, therefore medicine discharges to the outside by inside, the route of experience is longer, prolonged slow-release time, and do not influence surrounding tissue and body fluid to the spongy bone carrier open into and infiltration, the process of bone defect repair is not hindered.Make that like this preparation process is easy, can finish under the normal temperature and pressure, do not relate to other chemical reagent, improved the safety of preparation, be fit to large-scale production, the sustained release profile in vivo test time also obtains prolonging, and has simplified preparation process greatly, has improved the effect that safety has strengthened treatment simultaneously.
Description of drawings
Below in conjunction with the embodiment accompanying drawing this utility model is described further.
Fig. 1 is that embodiment minor axis transverse section is seen;
Figure 2 shows that the sight of embodiment major axis transverse section;
The whole volume rendering that Figure 3 shows that embodiment is seen.
Among the figure: 1, the spongy bone carrier of bone morphogenetic protein; 2, slow-released carrier.
The specific embodiment
Embodiment 1 is the sight of embodiment 1 minor axis transverse section as shown in Figure 1: the calcium phosphate bone cement post is nested in the spongy bone carrier 1 that is compounded with bone morphogenetic protein (BMP), and four gray circular region representatives are evenly distributed on 1 * 1cm
2The plane on slow-released carrier 2, it is calcium phosphate bone cement cylinder transverse section, it is the slow-released carrier 2 that is compounded with in the spongy bone carrier 1 of bone morphogenetic protein, slow-released carrier 2 is diameter 1mm, length is 15mm, the cylinder of centre-to-centre spacing border 4mm, adjacent column body centre-to-centre spacing are antibiotic calcium phosphate bone cement of containing of 3mm.
As shown in Figure 2, see for embodiment 1 major axis transverse section: two grey rectangle Regional Representative slow-released carriers 2 are cylindrical calcium phosphate bone cement column length axle transverse section, and length equally is 15mm with whole utility model, and width is cylinder diameter 1mm.
As shown in Figure 3, see for the volume rendering of whole utility model: external frame is the border of whole embodiment 1, and the spongy bone carrier 1 of bone morphogenetic protein is 1 * 1 * 1.5cm
3Cube, at its 1 * 1cm
2Upper edge, plane major axis the reserving hole of 4 equally distributed diameter 1mm is arranged, be embedded with slow-released carrier 2 in the middle of the reserving hole of the spongy bone carrier 1 of bone morphogenetic protein; Quantity, the shape of the reserving hole on the spongy bone carrier 1 of the quantity of slow-released carrier 2, shape and bone morphogenetic protein are identical, and size matches.The calcium phosphate bone cement slow releasing carrier of medication 2 of middle four solid Lycoperdon polymorphum Vitt cylinders for embedding.The spongy bone carrier 1 of bone morphogenetic protein has the bone morphogenetic protein of 8mg.
The preparation method of Anti-infective bone transplantation carrier is as follows:
Obtain calf metaphysis spongy bone (animal quarantine is qualified, butcher the back 2h in), be prepared into each parameter cube as shown in Figure 1 after, 3mmol/LNaN
3Flushing, 5min/ time, methanol: (mL: mixed defatting loss of thick fluid fat 24h mL), distilled water flushing 3 times 5min/ time, is followed the sequential 2mol/L of using CaCl to anhydrous alcohol=1: 1
2, 0.5mol/L EDTA, 4mol/L LiCl extracting 24h respectively slough albumen, above-mentioned defat deproteinization process repeats to drop into after 3 times decalcification 5min among the HCL of 0.6M/L, distilled water wash repeatedly to pH value be 6.0, soak dialysis 24 hours, fume hood dries.Electric hand drill evenly bores 4 holes that diameter is 1mm at carrier 1cm * 1cm face upper edge major axis, soak above-mentioned carrier with homogenizer and deionized water after with the complete homogenate of BMP, in freezer dryer-continue 24h under the condition of 93Kpa, make BMP be uniformly distributed in the spongy bone carrier 1 of bone morphogenetic protein, the compound BMP 8mg of each carrier.
The cavity of preparation diameter 1mm on bone-grafting material, under the room temperature with the calcium phosphate bone cement powder: consolidation liquid: gentamycin powder: BMP=6: (g: mL: g: ratio g) was made pasty state with above-mentioned powder in 3: 0.12: 0.03, with the 5mL syringe said mixture is poured in the hole, the back suitably vibrates on agitator and makes mixture tamp, room temperature makes its spontaneous curing through 20min down, make this utility model, space structure as shown in Figure 2, every carrier phosphoric acid calcium bone cement 400mg, gentamycin 8mg.Pack, oxirane (400mg/L, normal pressure 2h) sterilization is standby.
Said mixture is poured in the hole, and vibration is tamped mixture, and it is solidified, also can be for by be placed into the medicine slow-released carrier 2 of other type in the described carrier material in the above by the method that embeds.Bone-grafting material remove filling other position of above-mentioned material by the even compound bone morphogenetic protein of cryodesiccated method (BMP) 8mg, also can be by pouring into, the method for negative pressure-pumping is with the compound above-mentioned position of advancing bone-grafting material of skeletal growth factor.
The aufbauprinciple of embodiment 2 its Anti-infective bone transplantation carriers and prepared process are with embodiment 1, the cube that the described calf metaphysis spongy bone that fresh quarantine is qualified is prepared into can be other geometry, as tri-prismoid, reserving hole at 6 equally distributed diameter 1mm of its cross section upper edge major axis preparation, make the bone morphogenetic protein (BMP) of the compound 8mg that enters of each carrier by cryodesiccated method, because of slow-released carrier 2 quantity of carrier dimensions shape and placement are to come surely according to the damaged situation of bone, slow-released carrier 2 is tri-prismoids of 6 gelatin or collagen-based materials.
The aufbauprinciple of embodiment 3 its Anti-infective bone transplantation carriers and prepared process are with embodiment 1, and the cube that the described calf metaphysis spongy bone that fresh quarantine is qualified is prepared into is at its 1 * 1cm
2The reserving hole of 9 equally distributed diameter 1mm of upper edge, plane major axis preparation, make the bone morphogenetic protein (BMP) of the compound 8mg that enters of each carrier by cryodesiccated method, because of slow-released carrier 2 quantity of carrier dimensions shape and placement are to come surely according to the damaged situation of bone, slow-released carrier 2 is cubes of 9 fibrin glue materials.Described carrier material can be antigen human or animal bone piece, skeletal grain nature bone carrier, calcium phosphate, hydroxyapatite, polylactic acid, polyglycolic acid artificial bone carrier; Described skeletal growth factor can be the natural bone morphogenetic protein(BMP) (BMP) of animal origin or gene recombinaton Human Bone Morphogenetic Proteins-4 (rhBMP) and basic fibroblast growth factor natural origin or gene recombinaton (FGF or rhFGF) that genetic engineering is produced; Described medicine can be antibiotic, antituberculotics or tumor chemotherapeutic drug.
Claims (7)
1. Anti-infective bone transplantation carrier is characterized in that: being compounded with in the spongy bone carrier of bone morphogenetic protein has slow-released carrier.
2. a kind of Anti-infective bone transplantation carrier according to claim 1 is characterized in that: the spongy bone carrier of described bone morphogenetic protein is a cube, and the reserving hole of slow-released carrier is arranged at one upper edge, a plane major axis.
3. a kind of Anti-infective bone transplantation carrier according to claim 1 is characterized in that: be embedded with slow-released carrier in the middle of the reserving hole of the spongy bone carrier of described bone morphogenetic protein.
4. a kind of Anti-infective bone transplantation carrier according to claim 3 is characterized in that: quantity, the shape of the reserving hole on the spongy bone carrier of the quantity of described slow-released carrier, shape and bone morphogenetic protein are identical, and size matches.
5. a kind of Anti-infective bone transplantation carrier according to claim 1 is characterized in that: described slow-released carrier is the slow-released carrier of calcium phosphate bone cement or gelatin or collagen and fibrin glue material.
6. a kind of Anti-infective bone transplantation carrier according to claim 1 is characterized in that: the spongy bone carrier of described bone morphogenetic protein is 1 * 1 * 1.5cm
3Cube, at its 1 * 1cm
2Upper edge, plane major axis the reserving hole of 2-9 equally distributed diameter 1mm is arranged.
7. a kind of Anti-infective bone transplantation carrier according to claim 6, it is characterized in that: described slow-released carrier is diameter 1mm, length is 15mm, cylinder or the corner angle cylinder of centre-to-centre spacing border for being symmetrically distributed, adjacent column body or corner angle cylinder centre-to-centre spacing are the equally spaced antibiotic calcium phosphate bone cement that contains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2006200784096U CN201012188Y (en) | 2006-02-17 | 2006-02-17 | Infection-resisted bone grafting carrier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2006200784096U CN201012188Y (en) | 2006-02-17 | 2006-02-17 | Infection-resisted bone grafting carrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201012188Y true CN201012188Y (en) | 2008-01-30 |
Family
ID=39023975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2006200784096U Expired - Fee Related CN201012188Y (en) | 2006-02-17 | 2006-02-17 | Infection-resisted bone grafting carrier |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201012188Y (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103990180A (en) * | 2014-05-26 | 2014-08-20 | 中国人民解放军第四军医大学 | Preparation method and application of deproteinated decalcification bone matrix implantable microcarrier |
-
2006
- 2006-02-17 CN CNU2006200784096U patent/CN201012188Y/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103990180A (en) * | 2014-05-26 | 2014-08-20 | 中国人民解放军第四军医大学 | Preparation method and application of deproteinated decalcification bone matrix implantable microcarrier |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schek et al. | Combined use of designed scaffolds and adenoviral gene therapy for skeletal tissue engineering | |
| US10751185B2 (en) | Treatment of skeletal voids with implantable substrate hydrated with bone marrow concentrate | |
| Kumar et al. | Additively manufactured biphasic construct loaded with BMP-2 for vertical bone regeneration: A pilot study in rabbit | |
| Chen et al. | Periodontal regeneration using novel glycidyl methacrylated dextran (Dex-GMA)/gelatin scaffolds containing microspheres loaded with bone morphogenetic proteins | |
| US7713542B2 (en) | Three dimensional cell protector/pore architecture formation for bone and tissue constructs | |
| Strobel et al. | Induction of bone formation in biphasic calcium phosphate scaffolds by bone morphogenetic protein‐2 and primary osteoblasts | |
| Li et al. | Porous chitosan bilayer membrane containing TGF-β1 loaded microspheres for pulp capping and reparative dentin formation in a dog model | |
| CN1302821C (en) | Preparation method of calcium orthophosphate bone cement degradable to pore in human body | |
| Xie et al. | Icariin-loaded porous scaffolds for bone regeneration through the regulation of the coupling process of osteogenesis and osteoclastic activity | |
| Kim et al. | Volumetric bone regenerative efficacy of biphasic calcium phosphate‐collagen composite block loaded with rhBMP‐2 in vertical bone augmentation model of a rabbit calvarium | |
| Wei et al. | A novel injectable scaffold for cartilage tissue engineering using adipose‐derived adult stem cells | |
| Liu et al. | Tissue engineering of a vascularized bone graft of critical size with an osteogenic and angiogenic factor-based in vivo bioreactor | |
| CN103764054B (en) | Bone substitute material body and manufacture method thereof | |
| Grosfeld et al. | Long-term biological performance of injectable and degradable calcium phosphate cement | |
| Yang et al. | Graded porous β-tricalcium phosphate scaffolds enhance bone regeneration in mandible augmentation | |
| Shin et al. | The effects of Erh BMP‐2‐/EGCG‐coated BCP bone substitute on dehiscence around dental implants in dogs | |
| Lei et al. | Core–shell bioactive ceramic robocasting: Tuning component distribution beneficial for highly efficient alveolar bone regeneration and repair | |
| CN102131529A (en) | Bone defect filler not adsorbing bone growth factor and not inhibiting the activity of the same | |
| CN102036694A (en) | Bioceramic and biopolymer composite | |
| Vaquette et al. | Recent advances in vertical alveolar bone augmentation using additive manufacturing technologies | |
| Luo et al. | An in vivo comparative study of the gelatin microtissue‐based bottom‐up strategy and top‐down strategy in bone tissue engineering application | |
| US20150283089A1 (en) | Bilayered Calcium Sulfate/Calcium Phosphate Space-Making Composites with Multiple Drug Delivery Capabilities | |
| CN201012188Y (en) | Infection-resisted bone grafting carrier | |
| Nokhbatolfoghahaei et al. | Prefabrication technique by preserving a muscular pedicle from masseter muscle as an in vivo bioreactor for reconstruction of mandibular critical‐sized bone defects in canine models | |
| Jo et al. | Effects of different rhBMP-2 release profiles in defect areas around dental implants on bone regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080130 Termination date: 20110217 |